arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

IDEXX LABORATORIES INC /DE

IDXX
$522.00 ▲ +0.46 (+0.09%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
72 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

IDEXX LABORATORIES INC /DE shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $41.2B
Dividend Yield
Revenue Growth 9.7%
Op. Margin 35.0%
ROIC 18.0%
FCF / Share $4.08
Trailing P/E 121.7x
Price / Book 25.5x
FCF Yield 0.8%
Debt / Equity 0.19
info Valuation on last close. End-of-day price, Sep 23, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.22B
↑ +9.7%
Net Income Profit after all expenses
$278.45M
↑ +14.7%
Operating Margin Operating profit as % of sales
35.0%
↑ +10.1% 88th
FCF / Share Free cash flow per share
$4.08
↑ +38.9%
Long-Term Debt Long-term obligations
$299.87M
— 0.0%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
87
Returns
98
Financial Health
79
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 72 quarters